Abstract

EFFICACY AND SAFETY OF IVABRADINE IN PATIENTS WITH CHRONIC STABLE HEART FAILURE

Elavarasi P.*, Ezhil Ramya J. and Vasanth S.

Abstract

INTRODUCTION: Chronic heart failure is associated with increasing incidence of mortality and morbidity. Unlike western countries where heart failure is a disease of elderly, in India it affects younger age group. The lifetime risk of developing HF at the age of 40 yr is 11.4 % for men and 15.4 % for women. Ivabradine is a novel specific and selective heart rate lowering agent that acts in sino-atrial node cells by selectively inhibiting the cardiac pacemaker in a dose dependant manner. OBJECTIVE: To evaluate the efficacy and safety of Ivabradine in patients with chronic stable heart failure prospectively. MATERIALS AND METHODS: Interventional, open label, prospective, single centered study conducted in the Out patient Department of Cardiology, Tirunelveli Medical College Hospital and 50 patients attending cardiology OPD receiving chronic heart failure therapy. End points noted were improvement in ejection fraction and improvement in left ventricular function. RESULTS: After treatment with Ivabradine, there were no patients with severe LV dysfunction at the end of 1 and 3 months when compared with 5 patients at the baseline. After treatment with study drug patients with moderate LV dysfunction was reduced to 20 at the end of 1 month and 6 patients at the end of 3 months when compared with 35 patients at the baseline. After treatment with study drug the improvement in ejection fraction% was (45.48±5.03) (p

Keywords: Chronic stable heart failure, Ivabradine, left ventricular function, Ejection fraction.